ARS Pharmaceuticals SPRY 深 沪
等待开盘 10-12 09:30:00 美东时间
4.23
-0.330
-7.24%
华盛通- 最 高4.555
- 今 开4.53
- 成交量 125.84万股
- 最 低 4.20
- 昨 收 4.56
- 总市值 4.21亿
- 52周最高 13.15
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 3.985
- 委 比 87.27%
- 总股本 9944.73万
- 历史最高 63.41
- 量 比 0.83
- 振 幅 7.79%
- 历史最低 2.55
- 每 手 1
- 风险率 1.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
ARS Pharmaceuticals, Inc. announced that its President and CEO, Donn Casale, will participate in two September investor conferences: the Wells Fargo Healthcare Conference in Boston on September 9, 2026, and the Cantor Global Healthcare Conference in New York on September 10 and 11, 2026. The company, which specializes in treatments for severe allergic reactions, markets neffy® (epinephrine nasal spray) and is developing ARS-2 for chronic spontane...
09-01 20:01
ARS Pharmaceuticals (SPRY) 2026财年第二季度业绩电话会议：neffy市场份额增长与成本重置
ARS Pharmaceuticals 2026年第二季度业绩电话会议：随着neffy获得更多市场份额，营收达到3370万美元，同时管理层削减成本，并旨在2027年实现现金收支平衡。
08-14 08:40
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
08-14 04:45
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q2营收0.34亿美元，同比增长114.2%；归母净利润亏损0.62亿美元，同比亏损扩大38.9%
华盛资讯8月14日讯，ARS Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.34亿美元，同比增长114.2%，归母净利润亏损0.62亿美元，同比亏损扩大38.9%。
08-14 04:37
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q2营收0.34亿美元，同比增长112.5%；归母净利润亏损0.62亿美元，同比亏损扩大37.8%
华盛资讯8月14日讯，ARS Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.34亿美元，同比增长112.5%，归母净利润亏损0.62亿美元，同比亏损扩大37.8%。
08-14 04:24
ARS Pharmaceuticals Announces Key Executive Leadership Departures
An update from ARS Pharmaceuticals ( ($SPRY) ) is now available. On July 15, 20...
07-18 05:36
Can ARS Pharma's New CEO Unlock Neffy's Potential?
On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026. The board appointed Donn Casale, the company’s current president, as CEO and a director, effective July 7, 2026....
07-10 01:37
ARS Pharmaceuticals appoints new CEO
ARS Pharmaceuticals (SPRY) appointed Donn Casale as chief executive officer and director, effective July 7, 2026, succeeding co-founder Richard Lowenthal. Richard Lowenthal stepped down as an employee...
07-08 04:35
ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no lon...
07-08 04:31
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
